DDInter763 DDInter1435
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Flurbiprofen {u} (Compound) resembles {v} (Compound) L-Phenylalanine
Flurbiprofen {u} (Compound) resembles {v} (Compound) Tiaprofenic acid
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketoprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Labetalol
Flurbiprofen {u} (Compound) binds {v} (Gene) UGT1A1
Flurbiprofen {u} (Compound) upregulates {v} (Gene) IKBKE
Flurbiprofen {u} (Compound) palliates {v} (Disease) osteoarthritis
Flurbiprofen {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Flurbiprofen {u} (Compound) downregulates {v} (Gene) RRP12
Flurbiprofen {u} (Compound) causes {v} (Side Effect) Inflammatory bowel disease
Flurbiprofen (Compound) resembles L-Phenylalanine (Compound)
Flurbiprofen (Compound) resembles Tiaprofenic acid (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Labetalol
Flurbiprofen (Compound) binds UGT1A1 (Gene)
Flurbiprofen (Compound) upregulates IKBKE (Gene)
Flurbiprofen (Compound) palliates osteoarthritis (Disease)
Flurbiprofen (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Flurbiprofen (Compound) downregulates RRP12 (Gene)
Flurbiprofen (Compound) causes Inflammatory bowel disease (Side Effect)